Medvi is one of the cheapest GLP-1 options available, while Shed charges more but backs it with a 10% weight loss money-back guarantee and four medication formats. This comparison helps you decide if the guarantee is worth the premium.
Platform Overview
Medvi is an ultra-budget GLP-1 telehealth platform charging $197-$247 per month, targeting cost-sensitive patients who prioritize low-cost medication access over complete support. The platform's model is deliberately lean: patients receive a prescription and basic clinical oversight, but intensive coaching and behavioral programming are not central features. Medvi appeals to self-directed patients who have researched GLP-1 medications, understand the treatment protocol, and primarily need a licensed prescribing pathway rather than extensive guidance. The tradeoff for the lower price is a more transactional clinical experience. FDA-approved GLP-1 treatment protocols that Medvi follows require medical oversight regardless of platform pricing tier.
Shed positions itself at a higher value tier than Medvi at $199-$499 per month, but the additional cost is justified by its dedicated weight loss coaching and 10% body weight loss guarantee. Shed's model recognizes that medication alone produces suboptimal results for many patients - a finding supported by behavioral support research published in JAMA. For patients who are uncertain whether they have the self-motivation to sustain GLP-1 adherence without structured support, Shed's coaching infrastructure provides a meaningful safety net. The guarantee further distinguishes Shed by making the platform financially accountable for outcomes.
Pricing Comparison
Medvi's $197-$247 per month pricing is among the lowest in the GLP-1 telehealth market, making it accessible to patients for whom cost is the primary barrier. At this price point, Medvi is delivering medication management at near-commodity pricing, which is a genuine service to patients who cannot afford higher-priced platforms. The cost savings are real, but the absence of complete coaching and outcome guarantees means patients absorb more of the behavioral and financial risk themselves. For highly self-motivated patients who will research and implement lifestyle modifications independently, Medvi's pricing can be the right economic choice.
NIH weight management guidance acknowledges cost as a significant access barrier.
Shed's $199-$499 per month pricing sits modestly above Medvi's floor, but the value differential is substantial. Shed's 10% weight loss guarantee shifts outcome risk from the patient to the platform - a fundamentally different financial relationship than Medvi's no-guarantee model. Patients who spend $247/month with Medvi and achieve minimal results have no recourse, while Shed's guarantee creates contractual accountability. For patients with a history of weight loss attempts, the modest premium at Shed may be a more rational investment when the outcome protection is factored into the calculation. The
CDC confirms that supported programs produce better long-term results than self-directed approaches.
Medication Options and Quality
Medvi offers semaglutide and, depending on availability, tirzepatide through compounding pharmacy channels. At its price point, Medvi is focused on efficient prescription delivery rather than premium pharmacy partnerships. The platform's compounding pharmacy sourcing should be verified by patients who have concerns about compound quality, as not all FDA-registered compounders operate at equivalent quality standards. Medvi's lean operational model means pharmacy oversight is primarily handled through compliance rather than active quality monitoring programs.
NEJM semaglutide trial data shows strong efficacy when medication quality is maintained, making pharmacy sourcing a critical evaluation point for budget platform patients.
Shed provides semaglutide and tirzepatide through licensed compounding pharmacies, with the platform's clinical team actively managing medication quality and dosing as part of the overall program. Tirzepatide's superior efficacy - with
NEJM data showing 20%+ average weight loss - is available to qualifying patients. Shed's medication management is integrated with its coaching program, meaning dose adjustments are coordinated with behavioral support rather than handled in isolation. This integration ensures patients receive appropriate guidance during the challenging early titration phase.
Medical Team and Support
Medvi provides licensed medical oversight for prescription decisions and safety monitoring, meeting the baseline clinical requirements for GLP-1 prescribing. However, the platform's minimal support model means patients should not expect intensive coaching, frequent check-ins, or proactive provider outreach. Medvi is designed for patients who are essentially managing their own weight loss journey and using the platform primarily for legal access to medication. This model can work well for patients with prior GLP-1 experience who understand titration and side effect management, but it is less appropriate for first-time GLP-1 users who may need more guidance. JAMA behavioral research consistently shows support intensity correlates with better outcomes.
Shed's medical support model includes licensed prescribers supported by dedicated weight loss coaches who provide the ongoing behavioral infrastructure that distinguishes the platform from minimal-support options like Medvi. Coaches at Shed are trained in weight loss-specific behavioral techniques and proactively check in during high-risk phases of the program. The
American Association of Clinical Endocrinology recommends combined pharmacological and behavioral treatment as the evidence-based standard for obesity management - a recommendation that Shed implements and Medvi largely does not.
Weight Loss Approach and Programs
Medvi's weight loss approach is medication-centric by design. The platform provides GLP-1 prescriptions, basic dosing guidance, and clinical safety monitoring, leaving the broader program design to the patient. This is not inherently problematic for all patients - those with strong self-direction, prior GLP-1 familiarity, or access to their own nutrition and fitness resources can achieve good results on Medvi. However,
research published in Obesity journal shows that GLP-1 outcomes are significantly improved when behavioral support accompanies pharmacotherapy. Patients who need structure, accountability, and guidance to optimize their program should recognize that Medvi's model requires them to supply those elements themselves.
Shed's approach integrates pharmacotherapy with structured coaching and anchors the entire program around its 10% weight loss guarantee. Every element of the patient experience is designed to produce measurable outcomes within the program timeline. Coaches work with patients on nutritional habits, physical activity, adherence challenges, and motivation - the full behavioral stack that medication alone cannot address. The guarantee creates strong incentive alignment: Shed's clinical team is motivated to help patients hit the target because the platform's reputation and terms depend on it.
User Experience and Satisfaction
Medvi's user experience reflects its budget positioning: functional, efficient, and unembellished. The platform handles prescription management and refills reliably, and patients who know what they want and need minimal hand-holding report satisfaction with the streamlined process. Patients who expect coaching, regular check-ins, or a rich program experience report disappointment, suggesting that expectation alignment is critical for Medvi satisfaction. The platform's low cost attracts a large volume of self-directed users, and community forums among GLP-1 users often include Medvi customers sharing their self-managed experiences. Patients should research independent reviews carefully before committing.
Shed's user experience is purpose-built for GLP-1 weight loss program management, with coaching touchpoints, progress tracking, and guarantee-oriented milestones integrated throughout. Users describe the coaching team as genuinely engaged rather than perfunctory, and the proactive check-in model means patients feel supported during the inevitable challenging periods of GLP-1 therapy. The platform's guarantee framework creates a shared accountability dynamic that changes the quality of the patient-provider relationship. The
NIH's research on adherence confirms that patients with stronger provider relationships maintain GLP-1 treatment more consistently.
How We Tested Medvi vs Shed
Our Comparison Methodology
This comparison is based on complete analysis supplemented by peer-reviewed research on weight loss treatment.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication information (FDA Wegovy Label), obesity treatment guidelines from the American Association of Clinical Endocrinology, and clinical efficacy data from The New England Journal of Medicine.
Research Foundation: We analyzed peer-reviewed studies including GLP-1 medication efficacy from Obesity and behavioral support impact from JAMA.
Pricing Analysis: All pricing reflects published rates as of March 2026, verified through official platform websites.
Service Verification: Platform capabilities, provider credentials, and service quality were evaluated through detailed review of service offerings.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Medvi vs Shed
Choose Medvi if: You are a highly self-directed patient with prior GLP-1 experience who primarily needs an affordable, legitimate prescribing channel and does not require coaching or behavioral support. Medvi's ultra-budget pricing makes GLP-1 access possible for cost-constrained patients who can manage their own program.
Choose Shed if: You want a structured weight loss program with dedicated coaching and outcome accountability. Shed's 10% weight loss guarantee and behavioral support infrastructure are worth the modest premium over Medvi for most patients, particularly those who are new to GLP-1 treatment or have experienced previous weight loss setbacks.
Bottom line: Medvi and Shed represent opposite ends of the GLP-1 telehealth support spectrum. Medvi is medication access at minimum cost; Shed is a complete program built around guaranteed results. For the majority of patients seeking meaningful, sustained weight loss, Shed's combination of coaching and outcome guarantee makes it the stronger clinical investment despite the higher price.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
